Background Degludec is an ultralong-acting, once-daily basal insulin that is approved for
use in adults, adolescents, and children with diabetes. Previous open-label studies have …

Importance Hypoglycemia, a serious risk for insulin-treated patients with type 2 diabetes,
negatively affects glycemic control. Objective To test whether treatment with basal insulin …

Methods In DEVOTE, patients with type 2 diabetes were randomised to receive insulin
degludec or insulin glargine U100 once daily. The primary outcome was the first occurrence …

Context Prior observational studies suggest that treatment with lithium may be associated
with reduced risk of suicide in bipolar disorder. However, these studies are biased toward …

Aims/hypothesis The double-blind Trial Comparing Cardiovascular Safety of Insulin
Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of …

Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like
peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for …

OBJECTIVE To determine the respective associations of premorbid glucagon-like peptide-1
receptor agonist (GLP1-RA) and sodium–glucose cotransporter 2 inhibitor (SGLT2i) use …

A new design for estimating the distribution of time to pregnancy is proposed and
investigated. The design is based on recording current durations in a cross‐sectional …

We previously reported results based on the examination of a gluten-and casein-free diet as
an intervention for children diagnosed with an autism spectrum disorder as part of the …

Objectives: To estimate adherence to lithium in a nationwide sample of all patients treated
with lithium and to characterize adherence according to gender and age. Methods …